These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34429969)

  • 1. Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TC-1 tumor-bearing mice with PD-1 blockade by modulating macrophage heterogeneity and the activation of CD8
    Ni G; Yang X; Li J; Wu X; Liu Y; Li H; Chen S; Fogarty CE; Frazer IH; Chen G; Liu X; Wang T
    Clin Transl Immunology; 2021; 10(8):e1335. PubMed ID: 34429969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Application of Temperature-Sensitive Gel Containing Caerin 1.1 and 1.9 Peptides on TC-1 Tumour-Bearing Mice Induced High-Level Immune Response in the Tumour Microenvironment.
    Ni G; Liu X; Li H; Fogarty CE; Chen S; Zhang P; Liu Y; Wu X; Wei MQ; Chen G; Zhang P; Wang T
    Front Oncol; 2021; 11():754770. PubMed ID: 34858827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caerin 1.1/1.9 Enhances Antitumour Immunity by Activating the IFN-α Response Signalling Pathway of Tumour Macrophages.
    Yang X; Liu X; Li J; Zhang P; Li H; Chen G; Zhang W; Wang T; Frazer I; Ni G
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
    Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
    Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesized natural peptides from amphibian skin secretions increase the efficacy of a therapeutic vaccine by recruiting more T cells to the tumour site.
    Pan X; Ma B; You X; Chen S; Wu J; Wang T; Walton SF; Yuan J; Wu X; Chen G; Wang Y; Ni G; Liu X
    BMC Complement Altern Med; 2019 Jul; 19(1):163. PubMed ID: 31277636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Proteomic Study of the Antiproliferative Activity of Frog Host-Defence Peptide Caerin 1.9 and Its Additive Effect with Caerin 1.1 on TC-1 Cells Transformed with HPV16 E6 and E7.
    Ni G; Liang D; Cummins SF; Walton SF; Chen S; Wang Y; Mounsey K; Wei MQ; Yuan J; Pan X; Liu X; Wang T
    Biomed Res Int; 2018; 2018():7382351. PubMed ID: 29862288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.
    Beyranvand Nejad E; Labrie C; van Elsas MJ; Kleinovink JW; Mittrücker HW; Franken KLMC; Heink S; Korn T; Arens R; van Hall T; van der Burg SH
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33879600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
    Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
    Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral IL-12 delivery via mesenchymal stem cells combined with PD-1 blockade leads to long-term antitumor immunity in a mouse glioblastoma model.
    Park J; Park SA; Kim YS; Kim D; Shin S; Lee SH; Jeun SS; Chung YJ; Ahn S
    Biomed Pharmacother; 2024 Apr; 173():115790. PubMed ID: 38431436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8
    LaPorte KM; Hernandez R; Santos Savio A; Malek TR
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
    Kato Y; Tabata K; Kimura T; Yachie-Kinoshita A; Ozawa Y; Yamada K; Ito J; Tachino S; Hori Y; Matsuki M; Matsuoka Y; Ghosh S; Kitano H; Nomoto K; Matsui J; Funahashi Y
    PLoS One; 2019; 14(2):e0212513. PubMed ID: 30811474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
    Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC
    Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869
    [No Abstract]   [Full Text] [Related]  

  • 18. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors.
    Khan SM; Desai R; Coxon A; Livingstone A; Dunn GP; Petti A; Johanns TM
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.